Contraception
Volume 82, Issue 6 , Pages 520-525 , December 2010

A pilot study of the Copper T380A IUD and oral levonorgestrel for emergency contraception

  • David K. Turok

      Affiliations

    • Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT 84132-2209, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 801 581 8995; fax: +1 801 585 5146.
    • ,
  • Shawn E. Gurtcheff

      Affiliations

    • Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT 84132-2209, USA
    • ,
  • Erin Handley

      Affiliations

    • Division of Public Health, Department of Family and Preventive Medicine, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    • ,
  • Sara E. Simonsen

      Affiliations

    • Division of Public Health, Department of Family and Preventive Medicine, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    • ,
  • Christina Sok

      Affiliations

    • Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT 84132-2209, USA
    • ,
  • Patricia Murphy

      Affiliations

    • College of Nursing, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA

Received 17 March 2010 ,Revised 27 May 2010 ,Accepted 1 June 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This research was supported by an anonymous foundation. David Turok receives research support in the form of product from Duramed Pharmaceuticals and has served on an advisory board for Bayer Healthcare.

☆☆ The findings from this report were presented as a poster at Reproductive Health 2009 in Los Angeles, CA, USA, in September 2009.

PII: S0010-7824(10)00352-5

doi: 10.1016/j.contraception.2010.06.001

Contraception
Volume 82, Issue 6 , Pages 520-525 , December 2010

Article Tools

* Image Usage & Resolution